Two Phase 3 clinical trials of filgotinib, co-developed by Gilead and Galapagos, yieldpositive results

yesterday (October 11), Gilead Sciences and Galapagos(http://announced the results of the 52-week trial in two phase 3 clinicaltrials (http://in patients with severe rheumatoid arthritis (RA) in two phase3 clinicaltrials, which were developed by the two companiesThe conclusion supports the efficacy, safety and tolerability shown by filgotinib in previously published 12-week and 24-week dataAbout Filgotinib
Filgotinib is a highly selective JAK1 inhibitor developed jointly by Gilead Sciences and GalapagosJAKs belongs to the cytoplasmic tyrosine kinase family, which functions as a signaling pathway that mediates cytokine (e.ginterferon) activation, with four JAK subtypesInhibitors of this kinase family have shown efficacy in treating certain inflammatory and autoimmune diseasesPrior to this, filgotinib has been used in a number of clinical trials to treat a variety of inflammatory diseases
The complete data from the two Phase 3 trials are the results of a trial in the treatment of patients with different types of rheumatoid arthritisIn the FINCH 1 trial, a total of 1,759 patients who had been treated with MTX but had poor response were involvedPreviously published results showed that after 12 weeks of treatment, the proportion of patients who received filgotinib treatment that reached ACR20(one of the american rheumatology assessment indicators) was significantly higher than that of the placebo group, reaching the main endpoint of the trial
In another 52-week FINCH 3 trial, filgotinib was treated as a single-drug therapy, or in combination with MTX, in patients who had never been treated with MTX Previously published results showed that after 24 weeks of treatment, the combination therapy of filgotinib and MTX significantly increased the proportion of patients who reached ACR20, reaching the main end of the trial, compared to MTX.　　Yesterday (October 11), Gilead Sciences and Galapagos announced the results of a 52-week trial of two Phase 3 clinical trials treating patients with severe rheumatoid arthritis (RA) in two phase3 clinical trials of the oral JAK1 inhibitor filgotinib 　　The conclusion supports the efficacy, safety and tolerability shown by filgotinib in previously published 12-week and 24-week data 　　About Filgotinib
Filgotinib is a highly selective JAK1 inhibitor developed jointly by Gilead Sciences and Galapagos JAKs belongs to the cytoplasmic tyrosine kinase family, which functions as a signaling pathway that mediates cytokine (e.g interferon) activation, with four JAK subtypes Inhibitors of this kinase family have shown efficacy in treating certain inflammatory and autoimmune diseases 　　Prior to this, filgotinib has been used in a number of clinical trials to treat a variety of inflammatory diseases 　　The study the complete data from the two Phase 3 trials published this time are the results of a trial in the treatment of different types of rheumatoid arthritis patients by filgotinib In the FINCH 1 trial, a total of 1,759 patients who had been treated with MTX but had poor response were involved 　　Previously published results showed that after 12 weeks of treatment, the proportion of patients who received filgotinib treatment that reached ACR20(one of the american rheumatology assessment indicators) was significantly higher than that of the placebo group, reaching the main endpoint of the trial 　　In another 52-week FINCH 3 trial, filgotinib was treated as a single-drug therapy, or in combination with MTX, in patients who had never been treated with MTX previously published results showed that after 24 weeks of treatment, the combination therapy of filgotinib and MTX significantly increased the proportion of patients who reached ACR20, reaching the main end of the trial